Investment
Features
FeesSafety
Academy
More
Pluang+

Ready Capital gets 'Reduce' consensus rating as insiders buy shares amid mixed analyst views.

Analyst Insights
23 Mar 2026
Defense World
View Source
Bearish
pluang ai news

Ready Capital Corp (NYSE:RC) has received a consensus "Reduce" rating from six brokerages, with two recommending sell and four hold. The average 12-month price target stands at $2.81, reflecting cautious sentiment. Despite this, a company director recently increased his stake by 16.1%, buying 30,000 shares at $1.95 each. The company reported a slight earnings beat last quarter but maintains negative profitability metrics. Ready Capital also announced a small quarterly dividend, signaling some confidence in cash flow. Institutional investors have adjusted their holdings recently, with 55.87% of shares owned by institutions. The stock trades near its 52-week low, indicating market concerns about its outlook.

More News

Sodexo wins major global catering contract with Meta for 130+ sites in 30+ countries

Sodexo wins major global catering contract with Meta for 130+ sites in 30+ countries

Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...

Market News
Bullish
2 hours ago
Thor Explorations stays on track with gold production and strong cash position in Q2 2026.

Thor Explorations stays on track with gold production and strong cash position in Q2 2026.

Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...

Company Fundamentals
Bullish
4 hours ago
Angelini Pharma completes $4.1B acquisition of Catalyst, expanding US presence and brain health leadership.

Angelini Pharma completes $4.1B acquisition of Catalyst, expanding US presence and brain health leadership.

Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...

Company Fundamentals
Bullish
4 hours ago
Greenwich LifeSciences' breast cancer drug shows strong Phase 2 results but faces funding risks ahead of Phase 3.

Greenwich LifeSciences' breast cancer drug shows strong Phase 2 results but faces funding risks ahead of Phase 3.

Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...

Analyst Insights
Bullish
4 hours ago
Ethereum breaks $1,900 resistance, fueled by strong buying and short liquidations

Ethereum breaks $1,900 resistance, fueled by strong buying and short liquidations

Ethereum (ETH) surged past the $1,894.89 resistance level, accelerating its recovery toward the $1,940–$1,950 zone after days of consolidation. This breakout was supported by lower-than-expected U.S. inflation data, which boosted risk appetite and bu...

Technical Signals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App